2012 Oncology Market Research Review

Published by: BCC Research

Published: Dec. 1, 2012 - 153 Pages

Table of Contents

CHAPTER 1 2012 ONCOLOGY MARKET RESEARCH REVIEW

FOREWORD

CHAPTER 2 MICRORNA RESEARCH TOOLS, DIAGNOSTICS AND THERAPEUTICS: GLOBAL MARKETS (REPORT BIO115A)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THIS STUDY

SCOPE AND FORMAT

METHODOLOGY AND INFORMATION SOURCES

INTENDED AUDIENCE

ANALYST CREDENTIALS

RELATED REPORTS

BCC ONLINE SERVICES

DISCLAIMER

SUMMARY

TABLE 1 GLOBAL MARKET FOR MICRORNA RESEARCH TOOLS, DIAGNOSTIC AND THERAPEUTIC PRODUCTS, THROUGH 2017 ($ MILLIONS)

FIGURE 1 GLOBAL MARKET FOR MICRORNA RESEARCH TOOLS, DIAGNOSTIC AND THERAPEUTIC PRODUCTS, 2010–2017 ($ MILLIONS)

INTRODUCTION TO MICRORNA RESEARCH

OVERVIEW

MICRORNA DISCOVERY

MICRORNA DEFINITION

BIOGENESIS OF MICRORNA

FIGURE 2 SCHEMATIC REPRESENTATION OF MICRORNA BIOGENESIS AND ITS EFFECT ON PROTEIN TRANSLATION

FUNCTION OF MICRORNA

MICRORNA MARKET OVERVIEW

Tools for Research of MicroRNA Molecules

TABLE 2 GLOBAL MARKET FOR REAGENTS AND TOOLS FOR DNA/RNA RESEARCH, THROUGH 2016 ($ BILLIONS)

MicroRNA as Biomarker and its Role in Bioprofiling and Diagnostics Products Development

TABLE 3 MARKET FOR CANCER PROFILING TECHNOLOGIES, THROUGH 2015 ($ BILLIONS)

MicroRNA as Therapeutics Target in Drug Discovery

IMPORTANCE OF PATENTS IN MICRORNA RESEARCH

TABLE 4 PATENTS AND PATENT APPLICATION SEARCH IN MICRORNA RESEARCH USING SPECIFIC KEY WORDS, THROUGH 2012

miR-34 Example

miR-122 Case

TABLE 5 NUMBER OF PATENTS AND PATENT APPLICATIONS IN MICRORNA RESEARCH ACCORDING TO ASSIGNEE

CHAPTER 3 BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS (REPORT BIO022E)

INTRODUCTION

STUDY BACKGROUND

STUDY GOAL AND OBJECTIVES

INTENDED AUDIENCE

SCOPE OF REPORT

METHODOLOGY AND INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC PUBLICATIONS

COMMERCIAL DRUGS

DEVELOPMENTAL DRUGS

TABLE 6 FDA APPROVAL PROCESS FOR NEW DRUGS

SUMMARY

TABLE 7 GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS)

FIGURE 3 GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS)

OVERVIEW

BRIEF HISTORY OF PLANT-DERIVED MEDICINES

TABLE 8 KEY DATES IN BOTANICAL MEDICINE

TABLE 9 WELL KNOWN PLANT-DERIVED DRUGS

OPPORTUNITY LIES BEYOND WHAT'S KNOWN

FIGURE 4 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED COMPOUNDS IN U.S., 2000–2005* (%)

KEY DRIVERS

KEY CHALLENGES

SIGNS OF INDUSTRY INVESTMENT

TABLE 10 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT

TABLE 11 KEY SIGNS OF INVESTMENT IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS

BOTANICAL DRUGS DEFINED

UNDERSTANDING THE REGULATORY PROCESS

TABLE 12 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY

THE FIRST APPROVED BOTANICAL

A GROWING PIPELINE

FIGURE 5 INDS IN THE FDA BY THERAPEUTIC AREA (NO.)

OVERALL PHARMA LANDSCAPE

TABLE 13 TOP PHARMA COMPANIES BY REVENUE, 2007 ($ BILLIONS)

MAJOR CLASSES OF PLANT DRUGS

Terpenes and Steroids

Terpenes

Steroids

Alkaloids and Glycosides

Alkaloids

Ergot Alkaloids

Morphine Alkaloids

Vinca Alkaloids

Glycosides

Cardiac Glycosides

Anthraglycosides

Phenols

E. Cava Algae

Flavonoids

Resveratrol

Coumarin

Catechins

Proanthocyanidins

INTELLECTUAL PROPERTY

PRODUCTION

MOVING PRODUCTION FORWARD

ARTEMISININ: A CASE STUDY

SUPPLY AND LEGAL ISSUES

TABLE 14 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-BASED MEDICINALS

DRUG DEVELOPMENT AND MANUFACTURE

TABLE 15 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES

CHAPTER 4 GLOBAL MARKETS FOR STEM CELLS (REPORT BIO035D)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

MARKET ANALYSES AND FORECASTS

METHODOLOGY

INTENDED AUDIENCE

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED REPORTS

SUMMARY

DEFINITIONS

APPLICATIONS

RESEARCH AND COMMERCIALIZATION

FUNDING

MARKET

TABLE 16 GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2016 ($ MILLIONS)

FIGURE 6 GLOBAL STEM CELL MARKET AND FORECASTS, 2010–2016 ($ MILLIONS)

OVERVIEW

CELLS

STEM CELLS

FIGURE 7 EARLY DEVELOPMENT OF EMBRYO

INDUCED PLURIPOTENT STEM CELLS

HPSCS

THE CANCER PROBLEM

CANCER STEM CELLS-A BROADER TOPIC

STEM CELL RESEARCH

HISTORY

EMBRYONIC STEM CELLS

Growth and Identification of ESCs

Stimulating ESCs to Differentiate

ADULT STEM CELLS

Mesenchymal Stem Cells (MSCs)

Haematopoietic Stem Cells (HSCs)

Neural Stem Cell (NSC)

Endothelial Progenitor Cell (EPC)

Epithelial Stem Cell (ESC)

Very Small Embryonic-Like Cell (VSEL)

CORD BLOOD STEM CELLS

INDUCED PLURIPOTENT STEM CELLS (IPSCS)

Nuclear Reprogramming

CELL-BASED THERAPEUTICS

EMBRYONIC-DERIVED STEM CELLS

ADULT/PROGENITOR-DERIVED STEM CELLS

ENGINEERED SCS FOR TRANSPLANTATION

THERAPEUTIC STEM CELL BANKING

STEM CELL-BASED BIOMEDICAL RESEARCH

CHAPTER 5 BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES: GLOBAL MARKETS (REPORT HLC106A)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE AND FORMAT

INTENDED AUDIENCE

METHODOLOGY

RELATED BCC STUDIES

ANALYST CREDENTIALS

SUMMARY

TABLE 17 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2016 ($ MILLIONS)

FIGURE 8 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2010–2016 ($ MILLIONS)

OVERVIEW

BREAST CANCER DIAGNOSTICS AND TRENDS

BREAST CANCER

Early Breast Cancer Detection

TABLE 18 POSSIBLE SIGNS OF BREAST CANCER

Imaging Tests

MAMMOGRAPHY

DIAGNOSTIC MAMMOGRAMS

TABLE 19 DIAGNOSTIC MAMMOGRAM FOR BREAST CANCER

Digital Mammograms

Usefulness of Mammography

MAGNETIC RESONANCE IMAGING OF THE BREAST

BREAST ULTRASOUND

DUCTAL LAVAGE AND NIPPLE ASPIRATION

BIOPSY

Fine Needle Aspiration Biopsy

Core Needle Biopsy

Vacuum-Assisted Biopsies

Surgical (Open) Biopsy

LYMPH NODE DISSECTION AND SENTINEL LYMPH NODE BIOPSY

Laboratory Examination

TYPES OF BREAST CANCER

TABLE 20 BREAST CANCER GRADES

DUCTAL CARCINOMA IN SITU

ESTROGEN RECEPTOR AND PROGESTERONE RECEPTOR STATUS

HER2/NEU STATUS

TABLE 21 BIOPSY OR SURGERY SAMPLE TESTING

GENE EXPRESSION PROFILING

TABLE 22 TESTS USED TO EVALUATE DIFFERENT GENE SETS

Test Usefulness

Imaging Tests to Determine if Breast Cancer Has Spread

TABLE 23 IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD

THE FUTURE OF BREAST CANCER DETECTION

DIAGNOSTIC TESTS AND THEIR VALUE IN BREAST CANCER TESTING

TABLE 24 HER2 TESTING AND VARIATIONS

NEED FOR BREAST CANCER SCREENING

OVERDIAGNOSIS

Diagnosis and Treatment Regimen

GUIDELINES FOR BREAST CANCER DETECTION

TABLE 25 GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK, ASYMPTOMATIC WOMEN

Breast Cancer Screening Recommendations

USPSTF BREAST CANCER SCREENING GUIDELINES

TABLE 26 BREAST CANCER SCREENING RECOMMENDATIONS BY THE USPSTF

BIOMARKERS AND DEVELOPMENT OF CANCER DIAGNOSTICS

BIOMARKERS AND CANCER

BIOMARKERS AND BREAST CANCER

TABLE 27 BREAST CANCER PROGNOSTIC FACTORS

TABLE 28 BREAST CANCER PREDICTIVE FACTORS

TABLE 29 RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT ARE POSITIVE FOR CANCER (%)

TABLE 30 FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE (%)

HER2

COMPANION DIAGNOSTICS

TARGETED THERAPIES

PREDICTIVE DIAGNOSTICS

TABLE 31 PREDICTIVE DIAGNOSTIC FEATURES

PREDICTIVE SAFETY BIOMARKERS

Commercialized Biomarker Tests

TABLE 32 CURRENT BIOMARKER TECHNOLOGIES

TABLE 33 BIOMARKER USES

BIOMARKERS AND DRUG THERAPY

INCREASED USE OF BIOMARKERS IN DRUG DEVELOPMENT AND CLINICAL TRIALS

OBSTACLES TO BIOMARKER DEVELOPMENT

TABLE 34 MAJOR ISSUES AND CHALLENGES

BIOMARKER TYPES

Predictive Biomarkers

Tumor Interstitial Fluid Biomarkers

Pharmacogenomic Biomarkers in Drug Labels

BENEFITS OF PHARMACOGENOMICS

TABLE 35 PHARMACOGENOMICS TESTS IN USE

BARRIERS TO PHARMACOGENOMICS PROGRESS

Biomarkers in Drug Labels

CLASSIFICATION OF BIOMARKERS

TABLE 36 BIOMARKERS FOR DRUG LABELS BASED ON SPECIFIC USE

TABLE 37 CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE

TABLE 38 CLINICALLY RELEVANT BIOMARKERS

CHAPTER 6 LIVER DISEASE TREATMENTS: THE GLOBAL MARKET (REPORT PHM057B)

INTRODUCTION

STUDY OBJECTIVES

REASONS FOR DOING THIS STUDY

INTENDED AUDIENCE

SCOPE OF THE STUDY

METHODOLOGY

INFORMATION SOURCES

ABOUT THE AUTHOR

RELATED BCC RESEARCH REPORTS

EXECUTIVE SUMMARY

TABLE 39 GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY REGION, THROUGH 2016 ($ MILLIONS)

FIGURE 9 GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY REGION, 2009–2016 ($ MILLIONS)

OVERVIEW

DEFINITIONS

LIVER

FUNCTIONS OF LIVER

Production of Bile

Storage of Fats, Carbohydrates, Proteins, Vitamins and Minerals

Regulation of Necessary Substances in the Blood

Synthesis of Coagulating Proteins

Removal of Harmful Substances

Other Functions

COMMON SYMPTOMS OF LIVER DISEASE

FATIGUE

JAUNDICE

SWOLLEN ABDOMEN

EFFECTS OF HORMONAL IMBALANCE

STOOL ABNORMALITIES

POLYDYPSIA AND POLYURIA

HEPATIC ENCEPHALOPATHY

SEXUAL DYSFUNCTION

NON-SPECIFIC SYMPTOMS OF LIVER DISEASE

LIVER DISEASE

TABLE 40 CLASSIFICATION OF LIVER DISEASE

MARKET BY DISEASE TYPE

TABLE 41 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, THROUGH 2016 ($ MILLIONS)

FIGURE 10 GLOBAL MARKET FOR DRUG USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2009–2016 ($ MILLIONS)

HEPATITIS

TABLE 42 GLOBAL MARKET FOR DRUGS USED TO TREAT HEPATITIS, THROUGH 2016 ($ MILLIONS)

FIGURE 11 GLOBAL MARKET FOR DRUGS USED TO TREAT HEPATITIS, 2009–2016 ($ MILLIONS)

Global Share

TABLE 43 GLOBAL SHARE FOR DRUGS USED TO TREAT HEPATITIS BY REGION, 2010 (%)

FIGURE 12 GLOBAL SHARE FOR DRUGS USED TO TREAT HEPATITIS BY REGION, 2010 (%)

LIVER TUMORS

TABLE 44 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, THROUGH 2016 ($ MILLIONS)

FIGURE 13 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2009–2016 ($ MILLIONS)

Global Share

TABLE 45 GLOBAL SHARE FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2010 (%)

FIGURE 14 GLOBAL SHARE FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2010 (%)

AUTOIMMUNE DISEASES

TABLE 46 GLOBAL MARKET FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, THROUGH 2016 ($ MILLIONS)

FIGURE 15 GLOBAL MARKET FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2009–2016 ($ MILLIONS)

Global Share

TABLE 47 GLOBAL SHARE FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2010 (%)

FIGURE 16 GLOBAL SHARE FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2010 (%)

ALCOHOL-INDUCED LIVER DISEASE

TABLE 48 GLOBAL MARKET FOR DRUGS USED TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, THROUGH 2016 ($ MILLIONS)

FIGURE 17 GLOBAL MARKET FOR DRUGS USED TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2009–2016 ($ MILLIONS)

Global Share

TABLE 49 GLOBAL SHARE OF ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2010 (%)

FIGURE 18 GLOBAL SHARE OF ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2010 (%)

CHRONIC LIVER DISEASE

TABLE 50 GLOBAL MARKET FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, THROUGH 2016 ($ MILLIONS)

FIGURE 19 GLOBAL MARKET FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2009–2016 ($ MILLIONS)

Global Share

TABLE 51 GLOBAL SHARE FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2010 (%)

FIGURE 20 GLOBAL SHARE FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2010 (%)

NON-ALCOHOLIC FATTY LIVER DISEASE

TABLE 52 GLOBAL MARKET FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, THROUGH 2016 ($ MILLIONS)

FIGURE 21 GLOBAL MARKET FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2009–2016 ($ MILLIONS)

Global Share

TABLE 53 GLOBAL SHARE FOR DRUGS USED TO TREAT NON ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2010 (%)

FIGURE 22 GLOBAL SHARE FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2010 (%)

MARKET SHARE BY DISEASE TYPE

TABLE 54 DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010 (%)

FIGURE 23 DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010 (%)

LIST OF TABLES

TABLE 1 GLOBAL MARKET FOR MICRORNA RESEARCH TOOLS, DIAGNOSTIC AND THERAPEUTIC PRODUCTS, THROUGH 2017 ($ MILLIONS)

TABLE 2 GLOBAL MARKET FOR REAGENTS AND TOOLS FOR DNA/RNA RESEARCH, THROUGH 2016 ($ BILLIONS)

TABLE 3 MARKET FOR CANCER PROFILING TECHNOLOGIES, THROUGH 2015 ($ BILLIONS)

TABLE 4 PATENTS AND PATENT APPLICATION SEARCH IN MICRORNA RESEARCH USING SPECIFIC KEY WORDS, THROUGH 2012

TABLE 5 NUMBER OF PATENTS AND PATENT APPLICATIONS IN MICRORNA RESEARCH ACCORDING TO ASSIGNEE

TABLE 6 FDA APPROVAL PROCESS FOR NEW DRUGS

TABLE 7 GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS)

TABLE 8 KEY DATES IN BOTANICAL MEDICINE

TABLE 9 WELL KNOWN PLANT-DERIVED DRUGS

TABLE 10 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT

TABLE 11 KEY SIGNS OF INVESTMENT IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS

TABLE 12 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY

TABLE 13 TOP PHARMA COMPANIES BY REVENUE, 2007 ($ BILLIONS)

TABLE 14 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-BASED MEDICINALS

TABLE 15 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES

TABLE 16 GLOBAL STEM CELL MARKET AND FORECASTS, THROUGH 2016 ($ MILLIONS)

TABLE 17 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, THROUGH 2016 ($ MILLIONS)

TABLE 18 POSSIBLE SIGNS OF BREAST CANCER

TABLE 19 DIAGNOSTIC MAMMOGRAM FOR BREAST CANCER

TABLE 20 BREAST CANCER GRADES

TABLE 21 BIOPSY OR SURGERY SAMPLE TESTING

TABLE 22 TESTS USED TO EVALUATE DIFFERENT GENE SETS

TABLE 23 IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD

TABLE 24 HER2 TESTING AND VARIATIONS

TABLE 25 GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK, ASYMPTOMATIC WOMEN

TABLE 26 BREAST CANCER SCREENING RECOMMENDATIONS BY THE USPSTF

TABLE 27 BREAST CANCER PROGNOSTIC FACTORS

TABLE 28 BREAST CANCER PREDICTIVE FACTORS

TABLE 29 RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT ARE POSITIVE FOR CANCER (%)

TABLE 30 FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE (%)

TABLE 31 PREDICTIVE DIAGNOSTIC FEATURES

TABLE 32 CURRENT BIOMARKER TECHNOLOGIES

TABLE 33 BIOMARKER USES

TABLE 34 MAJOR ISSUES AND CHALLENGES

TABLE 35 PHARMACOGENOMICS TESTS IN USE

TABLE 36 BIOMARKERS FOR DRUG LABELS BASED ON SPECIFIC USE

TABLE 37 CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE

TABLE 38 CLINICALLY RELEVANT BIOMARKERS

TABLE 39 GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY REGION, THROUGH 2016 ($ MILLIONS)

TABLE 40 CLASSIFICATION OF LIVER DISEASE

TABLE 41 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, THROUGH 2016 ($ MILLIONS)

TABLE 42 GLOBAL MARKET FOR DRUGS USED TO TREAT HEPATITIS, THROUGH 2016 ($ MILLIONS)

TABLE 43 GLOBAL SHARE FOR DRUGS USED TO TREAT HEPATITIS BY REGION, 2010 (%)

TABLE 44 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, THROUGH 2016 ($ MILLIONS)

TABLE 45 GLOBAL SHARE FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2010 (%)

TABLE 46 GLOBAL MARKET FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, THROUGH 2016 ($ MILLIONS)

TABLE 47 GLOBAL SHARE FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2010 (%)

TABLE 48 GLOBAL MARKET FOR DRUGS USED TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, THROUGH 2016 ($ MILLIONS)

TABLE 49 GLOBAL SHARE OF ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2010 (%)

TABLE 50 GLOBAL MARKET FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, THROUGH 2016 ($ MILLIONS)

TABLE 51 GLOBAL SHARE FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2010 (%)

TABLE 52 GLOBAL MARKET FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, THROUGH 2016 ($ MILLIONS)

TABLE 53 GLOBAL SHARE FOR DRUGS USED TO TREAT NON ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2010 (%)

TABLE 54 DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010 (%)

LIST OF FIGURES

FIGURE 1 GLOBAL MARKET FOR MICRORNA RESEARCH TOOLS, DIAGNOSTIC AND THERAPEUTIC PRODUCTS, 2010–2017 ($ MILLIONS) 7

FIGURE 2 SCHEMATIC REPRESENTATION OF MICRORNA BIOGENESIS AND ITS EFFECT ON PROTEIN TRANSLATION 9

FIGURE 3 GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2013 ($ BILLIONS) 27

FIGURE 4 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED COMPOUNDS IN U.S., 2000–2005* (%) 31

FIGURE 5 INDS IN THE FDA BY THERAPEUTIC AREA (NO.) 39

FIGURE 6 GLOBAL STEM CELL MARKET AND FORECASTS, 2010–2016 ($ MILLIONS) 57

FIGURE 7 EARLY DEVELOPMENT OF EMBRYO 59

FIGURE 8 GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND DRUG TECHNOLOGIES, 2010–2016 ($ MILLIONS) 78

FIGURE 9 GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY REGION, 2009–2016 ($ MILLIONS) 115

FIGURE 10 GLOBAL MARKET FOR DRUG USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2009–2016 ($ MILLIONS) 122

FIGURE 11 GLOBAL MARKET FOR DRUGS USED TO TREAT HEPATITIS, 2009–2016 ($ MILLIONS) 124

FIGURE 12 GLOBAL SHARE FOR DRUGS USED TO TREAT HEPATITIS BY REGION, 2010 (%) 125

FIGURE 13 GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2009–2016 ($ MILLIONS) 126

FIGURE 14 GLOBAL SHARE FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY REGION, 2010 (%) 127

FIGURE 15 GLOBAL MARKET FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2009–2016 ($ MILLIONS) 129

FIGURE 16 GLOBAL SHARE FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2010 (%) 130

FIGURE 17 GLOBAL MARKET FOR DRUGS USED TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2009–2016 ($ MILLIONS) 131

FIGURE 18 GLOBAL SHARE OF ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2010 (%) 132

FIGURE 19 GLOBAL MARKET FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2009–2016 ($ MILLIONS) 134

FIGURE 20 GLOBAL SHARE FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY REGION, 2010 (%) 135

FIGURE 21 GLOBAL MARKET FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2009–2016 ($ MILLIONS) 136

FIGURE 22 GLOBAL SHARE FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 2010 (%) 137

FIGURE 23 DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010 (%)

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.